RANI (Rani Therapeutics Holdings) ROCE %: -75.52% (As of Mar. 2026)


RANI Rani Therapeutics Holdings Inc RANI
32 GF Score
Price $0.77
! 3 Warning Signs
View Full Analysis

What is Rani Therapeutics Holdings ROCE %?

Rani Therapeutics Holdings RANI +3.70% 32 ROCE % is -75.52% as of Mar. 2026. GuruFocus rates RANI with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Rani Therapeutics Holdings's annualized ROCE % for the quarter that ended in Mar. 2026 was -75.52%.

Rani Therapeutics Holdings  (NAS:RANI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Rani Therapeutics Holdings ROCE % Related Terms

Rani Therapeutics Holdings ROCE % Historical Data

* Premium members only.

The historical data trend for Rani Therapeutics Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rani Therapeutics Holdings ROCE % Chart

Rani Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -53.74 -55.35 -82.01 -154.65 -121.41

Rani Therapeutics Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -455.01 -30,657.78 0.00 -188.96 -75.52
RANI
32GF Score
Rani Therapeutics Holdings Inc RANI
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rani Therapeutics Holdings ROCE % Calculation

Rani Therapeutics Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-38.059/( ( (36.634 - 19.891) + (58.621 - 12.669) )/ 2 )
=-38.059/( (16.743+45.952)/ 2 )
=-38.059/31.3475
=-121.41 %

Rani Therapeutics Holdings's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-31.708/( ( (58.621 - 12.669) + (51.879 - 13.855) )/ 2 )
=-31.708/( ( 45.952 + 38.024 )/ 2 )
=-31.708/41.988
=-75.52 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -75.52% mean?
Rani Therapeutics Holdings (RANI) has a ROCE % of -75.52% as of Mar. 2026.
Is Rani Therapeutics Holdings' ROCE % too high?
Rani Therapeutics Holdings' current ROCE % is -75.52%. Overall, Rani Therapeutics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Rani Therapeutics Holdings' ROCE % compare to CGTX and INO?
Rani Therapeutics Holdings' ROCE % of -75.52% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Rani Therapeutics Holdings's current ROCE % is -75.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rani Therapeutics Holdings stock overvalued right now?
Rani Therapeutics Holdings (RANI) has a current ROCE % of -75.52%. The current ROCE % is -75.52%. Rani Therapeutics Holdings' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Rani Therapeutics Holdings (RANI), the current ROCE % is -75.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rani Therapeutics Holdings Business Description

Address 2051 Ringwood Avenue, San Jose, CA, USA, 95131
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
32GF Score

Get the complete analysis for RANI

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.77
Price